Clinical Trials

352 trials
RecentStart dateEnrollment
Terminated × Interventional × Pancreatic Neoplasms × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT06336148 2025-10-15

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Actym Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04383210 2025-04-03

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Elevation Oncology

Phase 2 Terminated
54 enrolled 11 charts
BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Fibromatosis, Gingival, 2, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Uterine Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03829501 2025-04-02

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Kymab Limited

Phase 1/2 Terminated
222 enrolled 49 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms